CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study

Neurology

Volumn 69, Issue 7, 2007, Pages 631-639

  Li, G ^a   Sokal, I ^a   Quinn, J F ^b   Leverenz, J B ^a   Brodey, M ^c   Schellenberg, G D ^a   Kaye, J A ^b   Raskind, M A ^a   Zhang, J ^a   Peskind, E R ^a   Montine, T J ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c Biosource Division   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BIOLOGICAL MARKER; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CEREBROSPINAL FLUID; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; FOLLOW UP; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; CLINICAL TRIAL; COMPARATIVE STUDY; GENE FREQUENCY; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RISK FACTORS; TAU PROTEINS;

EID: 34547890294     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000267428.62582.aa     Document Type: Article

References (35)

1. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
2. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004;1:213-225.
3. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
4. 1-42 and tau levels in CSF. Neurology 1999;52:1555-1562.
5. Blennow K, Vanmechelen E. CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003;61:235-242.
6. 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004;9:705-710.
7. 42 levels precede cognitive decline. Neurology 2005;65:323-325.
8. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 2005;19:220-225.
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
10. Wechsler W. Wechsler memory scale: revised. San Antonio, TX: The Psychological Corporation, 1987.
11. Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 1996;17:123-130.
12. Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. In: Wedding D, ed. The neuropsychology handbook: behavioral and clinical perspectives. New York: Springer Publishing Co., 1986:134-160.
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-344.
15. 42 in adults with normal cognition. Arch Neurol 2006;63:936-939.
16. Zhang J, Goodlett DR, Peskind ER, et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005;26:207-227.
17. Zhang J, Goodlett DR, Quinn JF, et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimer Dis 2005;7:125-133.
18. Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimer Dis 2006;9:293-348.
19. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
20. Galasko D. Biomarkers for Alzheimer's disease-clinical needs and application. J Alzheimer Dis 2005;8:339-346.
21. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
22. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:6-15.
23. Katzman R. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol 1976;33:217-218.
24. Clark C, Xie S, Chittams J, et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696-1702.
25. 42. Arch Neurol 2003;60:1202-1206.
26. Hu YY, He SS, Wang X, et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 2002;160:1269-1278.
27. Hampel H, Buerger K, Kohnken R, et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann Neurol 2001;49:545-546.
28. Ishiguro K, Ohno H, Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-94.
29. Kohnken R, Buerger K, Zinkowski R, et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000;287:187-190.
30. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
31. Hampel H, Teipel SJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 2004;17:350-354.
32. Maccioni RB, Lavados M, Guillon M, et al. Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 2006;27:237-244.
33. de Leon MJ, Klunk W. Biomarkers for the early diagnosis of Alzheimer's disease. Lancet Neurol 2006;5:198-199.
34. Buerger K, Ewers M, Andreasen N, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005;65:1502-1503.
35. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.